Genmab has been granted a patent for polypeptides and antibodies featuring a variant Fc domain that enhances Fc:Fc interactions, improving effector functions like CDC-response. The claim specifies a variant antibody with specific mutations in the Fc domain, contributing to its stability and efficacy. GlobalData’s report on Genmab gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Genmab, Personalized cancer vaccines was a key innovation area identified from patents. Genmab's grant share as of July 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Variant antibodies with improved effector functions
The granted patent US12049512B2 outlines a novel variant of a parent antibody characterized by specific mutations in its Fc domain and antigen-binding region. The primary claims detail a variant that includes an E345R mutation alongside either a K439E or S440K mutation, with the numbering of positions adhering to the EU Index. The patent further specifies that the antigen-binding region of this variant can target antigens expressed on cell membranes, particularly those associated with tumor cells. Additionally, the variant is identified as an IgG1 antibody, which is a common class of antibodies used in therapeutic applications.
The patent also encompasses various kits-of-parts that include the described antibody variants along with instructions for their use. Furthermore, it introduces a mixture of variant antibodies, which consists of two distinct IgG antibodies: one with the E345R and K439E mutations and another with the E345R and S440K mutations. These mixtures are also designed to bind to antigens on cell membranes, including tumor cell antigens, and may consist of IgG1 antibodies. The inclusion of kits for these mixtures, along with usage instructions, indicates a focus on practical applications in therapeutic settings, particularly in oncology.
To know more about GlobalData’s detailed insights on Genmab, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
